Diagnostics

Company announces U.S. launch of liver fibrosis assay HCV FibroSURE

Published in Hepatitis Weekly, April 12th, 2004

Laboratory Corp. of America Holdings (LabCorp) (LH) announced the availability of HCV FibroSURE, a noninvasive blood test for assessing liver status in hepatitis C virus (HCV) patients.

Developed by leading hepatologists at the Pitie-Salpetriere Hospital and BioPredictive in France, HCV FibroSURE is only available in the United States through LabCorp.

HCV FibroSURE provides an accessible alternative to liver biopsy, which physicians use to assess liver fibrosis and necroinflammatory activity in HCV patients. While liver biopsy has long been considered the gold standard to monitor the status of HCV and determine therapy options, it is an invasive...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-04-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry